Journal of Clinical Oncology, Vol 18, Issue 1
(January), 2000: 72
© 2000 American Society for Clinical Oncology
Pamidronate in Prevention of Bone Complications in Metastatic Breast Cancer: A Cost-Effectiveness Analysis
By Bruce E. Hillner,
Jane C. Weeks,
Christopher E. Desch,
Thomas J. Smith
From the Department of Internal Medicine, Virginia Commonwealth University and the Massey Cancer Center, Richmond, VA; and the Center for Outcomes and Policy Research, Dana-Farber Cancer Institute, Boston, MA.
Address reprint requests to B.E. Hillner, Virginia Commonwealth University, Box 980170, Richmond, VA 23298-0170; email hillner{at}hsc vcu.edu.
PURPOSE: Pamidronate is effective in reducing bony complications in patients with metastatic breast cancer who have known osteolytic lesions. However, pamidronate does not increase survival and is associated with additional financial costs and inconvenience. We conducted a post-hoc evaluation of the cost-effectiveness of pamidronate using the results of two randomized trials that evaluated pamidronate 90 mg administered intravenously every month versus placebo.
PATIENTS AND METHODS: The trials differed only in the initial systemic therapy administered (hormonal or chemotherapy). Total skeletal related events (SREs), including surgery for pathologic fracture, radiation for fracture or pain control, conservatively treated pathologic fracture, spinal cord compression, or hypercalcemia, were taken directly from the trials. Using a societal perspective, direct health care costs were assigned to each SRE. Each group’s monthly survival was equal and was projected to decline using observed median survivals. The cost of pamidronate reflected the average wholesale price of the drug plus infusion. The value or disutility of an adverse event per month was evaluated using a zero value (events avoided) or an assigned one (range, 0.2 to 0.8).
RESULTS: The cost of pamidronate therapy exceeded the cost savings from prevented adverse events. The difference between the treated and placebo groups was larger with hormonal systemic therapy than with chemotherapy (additional $7,685 compared with $3,968 per woman). The projected net cost per SRE avoided was $3,940 with chemotherapy and $9,390 with hormonal therapy. The cost-effectiveness ratios were $108,200 with chemotherapy and $305,300 with hormonal therapy per quality-adjusted year.
CONCLUSION: Although pamidronate is effective in preventing a feared, common adverse outcome in metastatic breast cancer, its use is associated with high incremental costs per adverse event avoided. The analysis is most sensitive to the costs of pamidronate and pathologic fractures that were asymptomatic or treated conservatively.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
C. H. Van Poznak and D. F. Hayes
Aromatase inhibitors for the treatment of breast cancer: is tamoxifen of historical interest only?
J Natl Cancer Inst,
September 20, 2006;
98(18):
1261 - 1263.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Botteman, V. Barghout, J. Stephens, J. Hay, J. Brandman, and M. Aapro
Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases
Ann. Onc.,
July 1, 2006;
17(7):
1072 - 1082.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Brauer, A. B. Rosen, N. V. Olchanski, and P. J. Neumann
Cost-Utility Analyses in Orthopaedic Surgery
J. Bone Joint Surg. Am.,
June 1, 2005;
87(6):
1253 - 1259.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. J. Smith, P. J. Coyne, P. S. Staats, T. Deer, L. J. Stearns, R. L. Rauck, R. L. Boortz-Marx, E. Buchser, E. Catala, D. A. Bryce, et al.
An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM)
Ann. Onc.,
May 1, 2005;
16(5):
825 - 833.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. C Gainford, G. Dranitsaris, and M. Clemons
Recent developments in bisphosphonates for patients with metastatic breast cancer
BMJ,
April 2, 2005;
330(7494):
769 - 773.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Mandelblatt, C. Armetta, K. R. Yabroff, W. Liang, and W. Lawrence
Descriptive Review of the Literature on Breast Cancer Outcomes: 1990 Through 2000
J Natl Cancer Inst Monographs,
October 1, 2004;
2004(33):
8 - 44.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. B. Elkin, M. C. Weinstein, E. P. Winer, K. M. Kuntz, S. J. Schnitt, and J. C. Weeks
HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis
J. Clin. Oncol.,
March 1, 2004;
22(5):
854 - 863.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. E. Hillner, J. N. Ingle, R. T. Chlebowski, J. Gralow, G. C. Yee, N. A. Janjan, J. A. Cauley, B. A. Blumenstein, K. S. Albain, A. Lipton, et al.
American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer
J. Clin. Oncol.,
November 1, 2003;
21(21):
4042 - 4057.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Canil and I. F. Tannock
Should Bisphosphonates Be Used Routinely in Patients With Prostate Cancer Metastatic to Bone?
J Natl Cancer Inst,
October 2, 2002;
94(19):
1422 - 1432.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Trippoli, M. Vaiani, A. Messori, E. Tendi, and B. E. Hillner
Survival Gain in Cost-Effectiveness Studies
J. Clin. Oncol.,
September 18, 2000;
18(18):
3318 - 3318.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. E. Hillner, J. N. Ingle, J. R. Berenson, N. A. Janjan, K. S. Albain, A. Lipton, G. Yee, J. S. Biermann, R. T. Chlebowski, and D. G. Pfister
American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast Cancer
J. Clin. Oncol.,
March 13, 2000;
18(6):
1378 - 1391.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
